Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 23%
Buy 8%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health Inc is experiencing significant growth, illustrated by a remarkable 70% year-over-year subscriber increase in Q4, bolstering its weight-loss segment and supporting expectations for sequential revenue growth. The company has diversified its offerings beyond the weight-loss category, including original specialties like sexual health, which lessens concentration risk compared to other direct-to-consumer platforms focused solely on weight-loss treatments. With strategic partnerships and advancements in drug development, Hims & Hers is well-positioned for sustained revenue growth, particularly as headwinds related to shipping diminish and as new specialties ramp up.

Bears say

Hims & Hers Health Inc. is experiencing a significant slowdown in revenue growth, as evidenced by disappointing earnings results for 4Q:25 and a weak revenue guidance for 1Q:26. The company's full-year 2026 revenue expectations have been lowered to $2.7 billion to $2.9 billion, which is notably below prior estimates, prompting a reassessment of its future financial performance and growth trajectory. Additionally, increasing legal and regulatory risks further contribute to the negative outlook for Hims & Hers, raising concerns about the sustainability of its business model in a challenging regulatory environment.

HIMS has been analyzed by 13 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 8% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 13 analysts, HIMS has a Hold consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.